Indenoquinoxaline-Based Spiro-Heterocycles: Synthesis, Structural Characterization, MEDT Study, and Dual Inhibition of Kinase-Related Enzymes EGFR and VEGFR2

Submitted by Anonymous on

Chemistry & BiodiversityEarly View e01597 RESEARCH ARTICLE Indenoquinoxaline-Based Spiro-Heterocycles: Synthesis, Structural Characterization, MEDT Study, and Dual Inhibition of Kinase-Related Enzymes EGFR and VEGFR2 Abdulmajeed Abdullah Alayyaf, Abdulmajeed Abdullah Alayyaf orcid.org/0009-0000-3377-4115 Department of Chemistry, College of Science, King Saud University, Riyadh,...

Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma

Submitted by Anonymous on

AbstractBackground Despite the crucial involvement of the EGFR pathway in hepatocellular carcinoma (HCC), the clinical efficacy of EGFR antibodies in HCC remains uncertain. While existing evidence suggests that immune dysfunction and tumor microenvironment alterations may contribute to treatment resistance, the...

SNX16 aggravates AngII-induced cardiac hypertrophy in mice via EGFR transactivation

Submitted by Anonymous on

Cardiac hypertrophy is an independent risk factor for heart failure (HF) which often leads to cardiovascular disease-related death worldwide. Here we show that the upregulated expressions of Sorting Nexin 16 (SNX16) are evident in the hypertrophic hearts. Cardiac-specific deletion of...

Efficacy of Almonertinib Versus Osimertinib as the First-Line Treatment for Non-Small Cell Lung Cancer With EGFR L858R Mutation and Prognostic Analysis: A Retrospective Comparative Cohort Study

Submitted by Anonymous on

Objectives Epidermal growth factor receptor (EGFR)–specific tyrosine kinase inhibitors show less efficacy against the EGFR L858R mutation than EGFR 19del, but no current head-to-head clinical trials 1 Introduction Lung cancer is the leading cause of cancer-related death worldwide [1, 2]....

Single-cell transcriptomic analysis reveals cellular and molecular changes in EGFR-positive lung adenocarcinoma before and after Furmonertinib treatment

Submitted by Anonymous on

AbstractBackground Lung adenocarcinoma (LUAD) frequently harbors activating mutations in the epidermal growth factor receptor (EGFR), making EGFR tyrosine kinase inhibitors (EGFR-TKIs) a critical component of targeted therapy. Although third-generation EGFR-TKIs, such as Furmonertinib, have improved outcomes for patients with EGFR-mutant...

EGFR-mutated advanced non-small cell lung cancer: new era of systemic therapy towards new standards of care - memo

Submitted by Anonymous on

SummaryPurpose This review summarizes current systemic treatment strategies for advanced EGFR-mutated non-small cell lung cancer (NSCLC), with a focus on novel first-line regimens and emerging concepts beyond progression. Methods Evidence from pivotal phase III trials and recent regulatory developments was...

Prevalence and therapeutic response of EGFR T790I mutation in NSCLC patients with acquired resistance to EGFR-TKIs: a retrospective cohort study

Submitted by Anonymous on

AbstractBackground The EGFR T790I mutation is a potential resistance mechanism against EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, its prevalence and clinical significance remain unexplored. We aim to delineate the mutational spectrum of EGFR T790I...

Subscribe to Newsfeed